Xeris Pharmaceuticals Inc (XERS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.05B
Last updated: Nov 17, 2026 at 4:41 PM ET
Xeris Pharmaceuticals Inc (XERS) Statistics
Xeris Pharmaceuticals (XERS) has a market cap of $3.05B and an enterprise value of $3.11B. Its share count is up 10.57% from a year earlier. Revenue grew 38.37% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 1.92% above the market cap, as debt exceeds cash.
| Market Cap | $3.05B |
|---|---|
| Enterprise Value | $3.11B |
| Latest price (Nov 17, 2026) | $16.80 |
Key Dates
The next earnings report is expected on Mar 1, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 1, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 8.3x and 62.3x.
| P/E Ratio | 140.0x |
|---|---|
| P/S Ratio | 8.3x |
| Forward P/S | 7.6x |
| P/B Ratio | 62.3x |
| P/OCF Ratio | 41.4x |
Enterprise Valuation
Counting debt and cash, the company is valued at 49.0x EBITDA.
| EV / Sales | 8.4x |
|---|---|
| EV / EBITDA | 49.0x |
| EV / EBIT | 66.5x |
Price Statistics
The stock is up 133.98% over 52 weeks and trades 56.57% above its 50-day average.
| Beta (1Y) | 0.12 |
|---|---|
| 52-Week Change | +133.98% |
| 1-Month Change | +53.42% |
| 3-Month Change | +91.34% |
| 6-Month Change | +183.78% |
| 5-Year Change | +475.81% |
| Total Return (1Y) | +133.98% |
| Total Return (3Y CAGR) | +111.69% |
| Total Return (5Y CAGR) | +47.74% |
| Return vs SPY (1Y) | +125.73% |
| Max Drawdown (1Y) | -34.93% |
| Max Drawdown (3Y) | -47.20% |
| Sharpe Ratio (1Y) | 1.57 |
| Correlation with SPY (1Y) | 0.03 |
| 50-Day Average | $10.73 |
| 200-Day Average | $7.92 |
| 52-Week Range | $5.25 to $16.98 |
| RSI (14 Days) | 85.8 |
| Average Volume (20 Days) | 3.37M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 2.15x current liabilities, and total debt is 3.89x shareholder equity.
| Current Ratio | 2.15x |
|---|---|
| Quick Ratio | 1.58x |
| Debt / Equity | 3.89x |
| Debt / EBITDA | 3.00x |
| Interest Coverage | 0.80x |
Returns and Efficiency
Return on invested capital is 15.50% over the last 12 months, against a 5-year average of -14.88%.
| Return on Equity (ROE) | -13.32% |
|---|---|
| Return on Assets (ROA) | -1.53% |
| Return on Invested Capital (ROIC) | 15.50% |
| Return on Capital Employed (ROCE) | 16.20% |
| ROA (5Y Average) | -20.79% |
| ROIC (5Y Average) | -14.88% |
| Asset Turnover | 0.93x |
| Inventory Turnover | 0.59x |
| Receivables Turnover | 5.81x |
| Cash Conversion Cycle | 615 days |
Scores
XERS has an Altman Z-Score of 4.27, in the safe zone above 2.99, and a Piotroski F-Score of 8 of 9, in the strong band of 8 or 9.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 4.27 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 8 of 9 |
| Piotroski Strength | Strong |
Income Statement
Revenue was $368.26M over the last 12 months.
| Revenue | $368.26M |
|---|---|
| Revenue Growth (YoY) | +38.37% |
| Gross Profit | $321.80M |
| Operating Income | $46.78M |
| Pretax Income | -$6.50M |
| Net Income | -$6.50M |
| EBITDA | $63.18M |
| EBIT | $46.78M |
| Reported EPS (TTM) | $0.12 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 11.53% of the $423.22M in total assets.
| Cash and Equivalents | $131.08M |
|---|---|
| Total Debt | $189.71M |
| Net Debt | $58.63M |
| Net Debt Per Share | $0.32 |
| Working Capital | $154.79M |
| Shareholder Equity | $48.78M |
| Book Value Per Share | $0.27 |
| Tangible Book Value | -$54.02M |
| Total Assets | $423.22M |
| Total Liabilities | $374.44M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | $73.65M |
|---|---|
| FCF Per Share | $0.40 |
| Depreciation and Amortization | $16.40M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 12.70%, against a 5-year average of -68.29%.
| Gross Margin | 87.38% |
|---|---|
| Operating Margin | 12.70% |
| Pretax Margin | -1.76% |
| Net Margin | -1.76% |
| EBITDA Margin | 17.16% |
| EBIT Margin | 12.70% |
| Gross Margin (5Y Average) | 80.48% |
| Operating Margin (5Y Average) | -68.29% |
| Net Margin (5Y Average) | -79.63% |
Growth
Revenue grew 38.33% a year over 3 years.
| Revenue Growth (3Y CAGR) | +38.33% |
|---|---|
| Revenue Growth (5Y CAGR) | +70.67% |
Dividends and Yields
XERS does not pay a dividend.
| Earnings Yield | 0.71% |
|---|---|
| Buyback Yield | -0.32% |
| Shareholder Yield | -0.32% |
Peer Position
Against 11 similar companies, XERS has the highest P/E.
P/E RatioPeer median 10.8x
P/S RatioPeer median 2.0x
ROICPeer median 7.08%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +9.85%
| P/E Ratio | 140.0x vs 10.8x median |
|---|---|
| P/S Ratio | 8.3x vs 2.0x median |
| ROIC | 15.50% vs 7.08% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +38.37% vs +9.85% median |
Analyst Forecast
Consensus estimates put revenue growth at 34.33% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +34.33% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About XERS
What is XERS's market cap?
Xeris Pharmaceuticals has a market cap of $3.05B. Its enterprise value, which adds debt and subtracts cash, is $3.11B.
What is XERS's P/E ratio?
Xeris Pharmaceuticals has a trailing P/E ratio of 140.0x.
How many shares of XERS are outstanding?
Xeris Pharmaceuticals has 180.94M shares outstanding. The count is up 10.57% from a year earlier.
Does XERS pay a dividend?
No. Xeris Pharmaceuticals does not pay a dividend.
How much debt does XERS have?
Xeris Pharmaceuticals has $189.71M of total debt and $131.08M of cash and equivalents, a net debt position of $58.63M.
XERS pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors